ExpreS2ion Biotechnologies Announces Research License Agreement with Mitsubishi Tanabe Pharma Corporation

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, has signed a two-year Research License Agreement granting Mitsubishi Tanabe Pharma Corporation access to use ExpreS2ion’s proprietary protein expression platform, ExpreS2 TM , in their Research and Development (R&D).The Research License Agreement The Research License Agreement grants Mitsubishi Tanabe Pharma Corporation the right to conduct research using ExpreS2ion’s proprietary ExpreS2system for two years.